Sector News

Teva closing up women’s health unit Theramex, thanks to lousy Zoely sales

September 25, 2014
Life sciences
We’ve seen what happens when a big drug goes generic. Plants close, sales reps lose their jobs. As the impending shutdown of a Teva Pharmaceutical Industries ($TEVA) unit shows, the same is true for an on-patent drug flop.
 
Theramex, a Teva women’s health unit located in Monaco, is planning to close its doors by 2016. R&D stops immediately. Teva will absorb the rest of the operation: commercial, supply chain and quality control. Almost 60 people will lose their jobs, according to the French newspaper Nice Matin, and they’re marching in the streets in protest.
 
One key reason, according to a French newspaper: the “commercial fiasco of Zoely.”
 
Zoely is a hormonal contraceptive, part of Teva’s women’s health business and among the generic giant’s short list of branded products. The Israel-based company acquired it along with Theramex in 2010, in a deal with Merck KGaA. When approved in Europe in 2011, Zoely was touted as a “natural” alternative to other combo pills, because the synthetic estrogen included is structurally identical to that produced by women’s bodies.
 
Later, Teva teamed up with Merck & Co. to develop Zoely in the U.S. But at the end of 2011, the FDA issued a complete response letter on the pill. Merck later launched a new trial of the drug, under the name NOMAC-E2, to check up on its efficacy and assess patterns of vaginal bleeding.
 
That study was wrapped up earlier this year, but the results haven’t been released. Meanwhile, the U.K.’s cost-effectiveness gatekeepers have said that the drug is most likely to be used as a second- or third-line option in “a small subgroup of women” who’ve found other combo pills unsuitable.
 
Teva has been on a cost-cutting drive, aiming to chop $2 billion from its cost base by 2017. But under new CEO Erez Vigodman, the company says it’s focusing on the positive. Its CFO, Eyal Desheh, recently said another round of cuts “will be counterproductive to growth.”
 
By Tracy Staton
 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach